TP53 and prostate carcinoma: In a more recent study using IHC, RNA microarray expression profiling, and DNA-targeted next-generation sequencing (NGS) for the evaluation of AVPCm in 28 prostate cancer patient-derived xenografts, we found that NGS had only slightly higher agreement scores with the loss-of-function transcriptional scores for TP53 compared to IHC, and both modalities had similar agreement to the loss-of-function transcriptional scores for RB1 and PTEN [23].